Oklahoma 2023 Regular Session

Oklahoma House Bill HB1615 Latest Draft

Bill / Engrossed Version Filed 03/22/2023

                             
 
ENGR. H. B. NO. 1615 	Page 1  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
ENGROSSED HOUSE 
BILL NO. 1615 	By: Worthen of the House 
 
   and 
 
  Howard of the Senate 
 
 
 
 
 
 
An Act relating to public health and safety; ame nding 
63 O.S. 2021, Section 2-402, which relates to the 
Uniform Controlled Dangerous Substances Act; 
providing separate penalties for unlawfully 
possessing controlled dangerous substances; 
authorizing the referral of violations to certain 
courts; authorizing municipalities to adopt 
ordinances; and providing an effective date. 
 
 
 
 
 
 
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA: 
SECTION 1.     AMENDATORY     63 O.S. 20 21, Section 2-402, is 
amended to read as follows: 
Section 2-402. A.  1.  It shall be unlawful for any person 
knowingly or intentionally to p ossess a controlled dangerous 
substance unless such substance was obtained directly, or pursuant 
to a valid prescription or order from a practitioner, while acting 
in the course of his or her professional practice, or except as 
otherwise authorized by this act. 
2.  It shall be unlawful for any person to purchase any 
preparation excepted from the provisions of the Unifo rm Controlled   
 
ENGR. H. B. NO. 1615 	Page 2  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
Dangerous Substances Act pursuant to Section 2 -313 of this title in 
an amount or within a time interval other than that permitt ed by 
Section 2-313 of this title. 
3.  It shall be unlawful for any person or business to sell, 
market, advertise or label any product containing ephedrine, its 
salts, optical isomers, or salts of optical isomers, for the 
indication of stimulation, mental alertness, weight loss, appetite 
control, muscle development, energy or other indication which is not 
approved by the pertinent federal OTC Final Monograph, Tentative 
Final Monograph, or FDA-approved new drug application or its legal 
equivalent.  In determ ining compliance with this requirement, the 
following factors shall be considered: 
a. the packaging of the product, 
b. the name of the product, and 
c. the distribution and promotion of the product, 
including verbal representations made at the point of 
sale. 
B.  1. Any person who violates this section is guilty of a 
misdemeanor punishable by confinement for not more than one (1) year 
and by a fine not exceeding One Thousand Dollars ($1, 000.00). 
2.  Any person who is convicted, receives a deferred sentence, 
or receives a suspended sentence for an offense provided for in this 
section, excluding the use of marijuana, and receives a second 
conviction within ten (10) years for an offense provided for in this   
 
ENGR. H. B. NO. 1615 	Page 3  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
section shall, upon conviction, be guilty of a misdemeanor 
punishable as such terms are provided for in paragraph 1 of this 
subsection.  In addition, the person may be required to: 
a. complete a substance abuse assessment or evaluation 
and follow the recommendatio ns subsequent thereto, and  
b. complete a drug diversion program for u p to one (1) 
year following the date of conviction as ordered by 
the court. If the person refuses or fails to complete 
the drug diversion program, the person may be subject 
to the terms of punishment provided for in paragraph 1 
of this subsection. 
3. Any person who is convicted, receives a deferred sentence, 
or receives a suspended sentence for an offense provided for in this 
section, excluding the use of marijuana, and receives a third or 
subsequent conviction within ten (10) years for an offense provided 
for in this section shall, upon conviction, be guilty of a 
misdemeanor punishable as such terms are provided for in paragraph 1 
of this subsection.  In addition, the person may be required to: 
a. complete a substance abuse assessment or evaluation 
and follow the recommendations subsequent thereto, and 
b. complete a drug diversion program for up to three (3) 
years following the date of conviction as ordered by 
the court. If the person refuses or fails to complete 
the drug diversion program, the person may be subject   
 
ENGR. H. B. NO. 1615 	Page 4  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
to the terms of punishment provided for in paragraph 1 
of this subsection. 
C. Violations under this section shall be referred to the state 
or to a municipal court of record for prosecution.  The offense may 
be prosecuted in a municipal court n ot of record if the court has 
the discretion to requir e any of the drug di version options outline d 
in subparagraphs a and b of paragraph s 2 and 3 of subsection B of 
this section as a component of a sentence, deferred sente nce, or 
suspended sentence. Municipal courts may adopt ordinances 
consistent with the provisions of this section. 
D. Any person convicted of any offense de scribed in this 
section shall, in addition to any fine imposed, pay a special 
assessment trauma-care fee of One Hundred Dollars ($100.00) to be 
deposited into the Trauma Care Assistance Revolving Fund created in 
Section 1-2530.9 of this title. 
SECTION 2.  This act shall become effective November 1, 2023.   
 
ENGR. H. B. NO. 1615 	Page 5  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
  
Passed the House of Representatives the 21st day of March, 2023. 
 
 
 
  
 	Presiding Officer of the House 
 	of Representatives 
 
 
Passed the Senate the ___ day of __________, 2023. 
 
 
 
  
 	Presiding Officer of the Senate